-+ 0.00%
-+ 0.00%
-+ 0.00%

Nutriband Founder Gareth Sheridan Returns as CEO to Lead Company Toward 2026 NDA Filing, Serguei Melnik Steps Down

Benzinga·10/27/2025 11:09:05
Listen to the news

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO.  

During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei Melnik had taken over the responsibilities of CEO. Mr Sheridan has returned to the position of CEO effective immediately and will guide the company through the final 2025 framework towards the target NDA filing in 2026 for AVERSA Fentanyl.

AVERSA FENTANYL has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA FENTANYL has the potential to reach peak annual US sales of $80 million to $200 million.1 While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and our goal is to make AVERSA FENTANYL available in all major medical markets in the world.  

The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

1 Health Advances Aversa Fentanyl market analysis report 2022